Reviewing Concordia International (CXRX) & AstraZeneca (AZN)

Concordia International (NASDAQ: CXRX) and AstraZeneca (NYSE:AZN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Concordia International and AstraZeneca, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Concordia International 2 0 0 0 1.00
AstraZeneca 1 6 12 0 2.58

AstraZeneca has a consensus price target of $38.00, suggesting a potential upside of 10.79%. Given AstraZeneca’s stronger consensus rating and higher possible upside, analysts plainly believe AstraZeneca is more favorable than Concordia International.


AstraZeneca pays an annual dividend of $1.37 per share and has a dividend yield of 4.0%. Concordia International does not pay a dividend. AstraZeneca pays out 57.8% of its earnings in the form of a dividend.

Valuation and Earnings

This table compares Concordia International and AstraZeneca’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Concordia International $816.16 million 0.04 -$1.32 billion ($35.54) -0.02
AstraZeneca $22.47 billion 3.87 $3.00 billion $2.37 14.47

AstraZeneca has higher revenue and earnings than Concordia International. Concordia International is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.


This table compares Concordia International and AstraZeneca’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Concordia International -282.00% N/A -0.07%
AstraZeneca 13.36% 35.56% 8.51%

Risk & Volatility

Concordia International has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Insider & Institutional Ownership

8.6% of Concordia International shares are owned by institutional investors. Comparatively, 14.8% of AstraZeneca shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


AstraZeneca beats Concordia International on 12 of the 14 factors compared between the two stocks.

Concordia International Company Profile

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Receive News & Ratings for Concordia International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia International and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply